Januvia family becomes King of ETC drugs over other antidiabetics
MSD Korea’s(CEO Dong-wook Hyun) diabetes type 2 treatments, the Januvia family has made the top of the 2015 4th quarter’s ETC market(based on the IMS’s amount of outpatient prescriptions).
The Januvia family, consisting of Januvia, a single sitagliptin DPP-4 inhibitor, Janumet, a sitagliptin/met...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
